Integra Lifesciences Holdings Corp.: Q2 FY2026 earnings call

What management said about Q2 FY2026, from the documents filed with the SEC on 2 October 2026: press release. Guidance figures: 4 lowered, 1 kept. The quarter’s numbers.

Key takeaways

July flooding damaged Cincinnati manufacturing facility: Flooding at Cincinnati facility in July 2026 caused damage to portions of facility, equipment, inventory and other assets, disrupting manufacturing of Specialty Surgical Technologies products. Source
Q3 revenue loss approximately $7 million: Cincinnati facility flooding disruption negatively impacted third quarter revenue by approximately $7 million through supply constraint effects across manufacturing. Source
Q4 revenue impact expected $15 to $20 million: Supply disruption from Cincinnati facility expected to negatively impact fourth quarter revenue by approximately $15 million to $20 million as recovery efforts continue. Source
Q3 revenue expected $410 to $412 million: Third quarter 2026 expected to report revenue of $410 million to $412 million. Preliminary results remain unaudited and subject to completion of financial closing procedures. Source
Q3 adjusted EPS expected $0.55 to $0.59: Third quarter adjusted earnings per diluted share expected to be $0.55 to $0.59, reflecting Cincinnati facility impact and revised business assumptions for remainder of year. Source
Full-year revenue guidance lowered to $1.634-1.654B: Full-year 2026 revenue guidance updated from $1.654 billion to $1.695 billion to $1.634 billion to $1.654 billion, reflecting revised Cincinnati facility impact and broader business assumptions. Source
Full-year adjusted EPS reduced to $2.30-2.40: Full-year 2026 adjusted earnings per diluted share guidance reduced from $2.40 to $2.50 to $2.30 to $2.40, reflecting Cincinnati facility disruption and revised business assumptions. Source
Return to full manufacturing operations Q2 2027: Cincinnati facility expected to return to full manufacturing operations during second quarter of 2027 as restoration activities and recovery efforts progress at site. Source

“While we are lowering our full-year revenue and adjusted EPS outlook for 2026, we continue to expect strong cash generation, including greater than $85 million of operating cash flow in the third quarter and approximately $190 million to $200 million for the full year”
Stuart Essig, Chairman and Chief Executive Officer

Guidance

Area	Period	Figure	Against last quarter
Q3 2026 revenue Source	third quarter of 2026	$410 million to $412 million	Lowered from $410 million to $425 million
Q3 2026 adjusted EPS Source	third quarter of 2026	$0.55 to $0.59	Lowered from $0.53 to $0.61
Full-year 2026 revenue Source	full year 2026	$1.634 billion to $1.654 billion	Lowered from $1.654 billion to $1.695 billion
Full-year 2026 adjusted EPS Source	full year 2026	$2.30 to $2.40	Lowered from $2.40 to $2.50
Full-year 2026 operating cash flow Source	full year 2026	approximately $190 million to $200 million	Kept

What changed from last quarter

Guidance lowered: Q3 2026 revenue guidance narrowed to $410-412M from $410-425M due to Cincinnati facility flooding disruption impacting revenue by approximately $7 million. Source
Guidance lowered: Q3 2026 adjusted EPS guidance adjusted to $0.55-0.59 from $0.53-0.61, narrowing range with upper end reduced due to Cincinnati facility impact. Source
Guidance lowered: Full-year 2026 revenue guidance cut to $1.634-1.654B from $1.654-1.695B reflecting revised Cincinnati facility disruption impact estimates across Q3 and Q4. Source
Guidance lowered: Full-year 2026 adjusted EPS guidance reduced to $2.30-2.40 from $2.40-2.50 reflecting Cincinnati facility disruption and revised full-year business assumptions. Source
New: Cincinnati facility flooded in July 2026, causing damage to facility, equipment, inventory and assets, resulting in operational disruption to Specialty Surgical Technologies manufacturing. Source

Cincinnati Facility Disruption

July flooding damaged Cincinnati manufacturing facility: Flooding at Cincinnati facility in July 2026 caused damage to portions of facility, equipment, inventory and other assets, disrupting manufacturing of Specialty Surgical Technologies products. Source
Business continuity and recovery plans activated: Company executed business continuity and recovery plans utilizing available inventory and activating established alternate sources of supply for certain products to support customers. Source
Q3 revenue loss approximately $7 million: Cincinnati facility flooding disruption negatively impacted third quarter revenue by approximately $7 million through supply constraint effects across manufacturing. Source
Q4 revenue impact expected $15 to $20 million: Supply disruption from Cincinnati facility expected to negatively impact fourth quarter revenue by approximately $15 million to $20 million as recovery efforts continue. Source

Third Quarter 2026 Results

Q3 revenue expected $410 to $412 million: Third quarter 2026 expected to report revenue of $410 million to $412 million. Preliminary results remain unaudited and subject to completion of financial closing procedures. Source
Q3 adjusted EPS expected $0.55 to $0.59: Third quarter adjusted earnings per diluted share expected to be $0.55 to $0.59, reflecting Cincinnati facility impact and revised business assumptions for remainder of year. Source
Preliminary results incorporate updated assumptions: Q3 preliminary results and updated guidance reflect revised assumptions regarding Cincinnati facility disruption and updated assumptions for broader business for remainder of year. Source

“Importantly, we remain encouraged by the progress we are making across the broader business, including improving product availability, the return of key products to market, and strengthening commercial execution.”
Stuart Essig, Chairman and Chief Executive Officer

Full-Year 2026 Guidance Revision

Full-year revenue guidance lowered to $1.634-1.654B: Full-year 2026 revenue guidance updated from $1.654 billion to $1.695 billion to $1.634 billion to $1.654 billion, reflecting revised Cincinnati facility impact and broader business assumptions. Source
Full-year adjusted EPS reduced to $2.30-2.40: Full-year 2026 adjusted earnings per diluted share guidance reduced from $2.40 to $2.50 to $2.30 to $2.40, reflecting Cincinnati facility disruption and revised business assumptions. Source
Guidance reflects revised Cincinnati facility impact: Preliminary results and updated full-year guidance reflect revised assumptions regarding Cincinnati facility disruption impact and updated assumptions for broader business performance. Source

Recovery Timeline and Insurance Coverage

Return to full manufacturing operations Q2 2027: Cincinnati facility expected to return to full manufacturing operations during second quarter of 2027 as restoration activities and recovery efforts progress at site. Source
Company assessing losses with insurance carrier: Company continues to work with insurance carrier to assess and document recoverable losses including both property damage and business interruption claims related to flooding. Source

Cash Generation and Business Progress

Strong operating cash flow expected $190-200M: Company continues to expect strong full-year 2026 operating cash flow of approximately $190 million to $200 million, with greater than $85 million in third quarter. Source
Improving product availability and key returns: Management encouraged by progress across broader business including improving product availability and return of key products to market despite Cincinnati disruption. Source
Strengthening commercial execution: Company strengthening commercial execution as part of broader business progress, demonstrating resilience and organizational alignment despite Cincinnati facility disruption. Source

Coming up, per management

Cincinnati facility return to full manufacturing Q2 2027: Company expects Cincinnati facility to return to full manufacturing operations during second quarter of 2027 as restoration and recovery activities continue. Source
SurgiMend product relaunch planned Q4 2026: Company initiated production at Braintree manufacturing facility and remains on track for planned fourth-quarter 2026 relaunch of SurgiMend product.

Risks management discussed

Operational: Cincinnati facility flooding in July 2026 caused damage to facility, equipment and inventory, resulting in ongoing operational disruption to manufacturing. Source
Financial: Flooding disruption negatively impacted Q3 by $7 million with expected Q4 impact of $15-20 million, with ongoing recovery costs and timeline uncertainty. Source
Financial: Insurance recovery uncertain as company continues to assess and document recoverable losses with insurance carrier for property damage and business interruption. Source
Operational: Return to full manufacturing operations not expected until Q2 2027 creates extended supply disruption risk for Specialty Surgical Technologies product portfolio. Source

Earlier plans management reported on

On track: Company expects Cincinnati facility to return to full manufacturing operations during Q2 2027 as recovery efforts progress. Source
On track: Company initiated production at Braintree facility and remains on track for planned Q4 2026 relaunch of SurgiMend.
On track: Company continues to expect approximately $190-200 million operating cash flow for full year 2026 despite Cincinnati disruption. Source

Summarised with AI from the documents the company filed with the SEC. Every point carries a quote that is checked word for word against the filing; a point whose quote is not found is left out. Source opens the filing at that line.

As filed with the SEC

Open the filing on EDGAR

Integra LifeSciences

Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance PRINCETON, N.J., October 2, 2026 - Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance.

“Our third quarter results were impacted by the July flooding event at our Cincinnati facility,” said Stuart Essig, Chairman and Chief Executive Officer. “Our teams have made significant progress executing recovery plans and supporting customers. As we have gained additional visibility into the recovery timeline and production ramp, we now have a clearer understanding of the expected impact on our third quarter results and full-year outlook.”

Mr. Essig continued, “While we are lowering our full-year revenue and adjusted EPS outlook for 2026, we continue to expect strong cash generation, including greater than $85 million of operating cash flow in the third quarter and approximately $190 million to $200 million for the full year. Importantly, we remain encouraged by the progress we are making across the broader business, including improving product availability, the return of key products to market, and strengthening commercial execution.”

Update on Cincinnati Facility

As previously disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and discussed on the second quarter earnings call, flooding at the Cincinnati facility in July 2026 caused damage to portions of the facility, equipment, inventory and other assets and resulted in operational disruption to the site. The facility manufactures and supports several products within the Company's Specialty Surgical Technologies portfolio.

Since the event, Integra has continued to execute its business continuity and recovery plans. The Company has utilized available inventory, activated established alternate sources of supply for certain products, and advanced restoration activities at the Cincinnati facility. These actions are intended to support customers and mitigate disruption while recovery efforts continue.

Based on its current assessment, Integra estimates that the flooding related supply disruption negatively impacted third quarter revenue by approximately $7 million and is expected to negatively impact fourth quarter revenue by approximately $15 million to $20 million. The Company expects a return to full manufacturing operations at the site during the second quarter of 2027.

Integra maintains property and business interruption insurance covering the Cincinnati facility. Based on its current assessment, the Company expects insurance recoveries to mitigate a substantial portion of the earnings impact associated with the disruption throughout the recovery period and until the facility returns to full manufacturing capacity. The Company continues to work with its insurance carrier to assess and document recoverable losses associated with the event, including both property damage and business interruption claims.

Preliminary Third Quarter Results and Updated Full-Year Guidance

For the third quarter of 2026, the Company expects to report revenue of approximately $410 million to $412 million and adjusted earnings per diluted share of $0.55 to $0.59. The preliminary results as set forth above are unaudited and remain subject to completion of the Company’s financial closing procedures.

For the full year 2026, the Company is updating its reported revenue outlook from a range of $1.654 billion to $1.695 billion to a range of $1.634 billion to $1.654 billion. The Company is updating its adjusted earnings per diluted share guidance from a range of $2.40 to $2.50 to a range of $2.30 to $2.40 and expects operating cash flow for the year to be approximately $190 million to $200 million.

The third quarter preliminary results and updated full-year guidance reflect revised assumptions regarding the expected impact of the July flooding event at the Cincinnati facility, as well as updated assumptions for the broader business for the remainder of the year.

The Company will report its third quarter 2026 financial results during a conference call in October 2026. A press release with the date, time and webcast information will be provided closer to the reporting date. The Company will provide additional information regarding its third quarter financial results and outlook for full-year 2026 at that time.

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra LifeSciences and its products, please visit www.integralife.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to: our preliminary unaudited results for the third quarter ended September 30, 2026; the preliminary estimated impact of the flooding event at our Cincinnati, Ohio manufacturing facility (the “Cincinnati facility”), including on revenue, adjusted earnings per diluted share and our financial condition and results of operations more generally; our fiscal 2026 guidance and our ability to deliver on such financial guidance; our expectations and progress in our recovery efforts, including timing and costs; and expected insurance coverage and recoveries. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Integra’s business and market, including: our ongoing assessment of the flooding event at the Cincinnati facility, related financial impacts, recovery efforts, potential asset impairments, unforeseen costs and insurance recoveries; and other risks identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2025, and information contained in subsequent filings with the Securities and Exchange Commission. Actual results could differ materially from anticipated or preliminary results or estimates. These forward-looking statements are made only as the date thereof, and Integra undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Relations:

Chris Ward

chris.ward@integralife.com

Media Contact:

Laurene Isip

laurene.isip@integralife.com